'lizbeth
07-19-2013, 09:16 PM
http://www.biooncology.com/research-education/hdis/her2-dimerization/
HER2 dimerization: a key component of oncogenic signaling in HER2+ breast cancer
The HER family
The HER family is composed of 4 receptor tyrosine kinases that must pair, or dimerize, to activate downstream signaling<sup>1</sup>:
EGFR (HER1)
HER2
HER3
HER4
The role of dimerization in HER2+ disease
Preclinical studies indicate that HER dimerization, or receptor pairing, is a critical step in HER activation.<sup>1</sup> While the receptors of the HER family are important mediators of normal cell growth and development, HER activation has also been implicated in cancer development and progression.<sup>10</sup>
In normal cell growth, dimerization is an essential requirement of HER functionality and signaling, and it occurs between 2 of the same receptors (homodimerization) or 2 different receptors (heterodimerization).<sup>1</sup>
However, in HER2+ disease, HER2 overexpression is associated with excessive dimerization that contributes to cell survival, cell proliferation, and tumorigenesis.<sup>6</sup>
http://www.biooncology.com/research-education/hdis/images/HERfamily.png <cite>The HER family of receptors.</cite>
(http://www.biooncology.com/research-education/hdis/images/HERfamily_lg.png) Ligand binding and HER activation
Each HER family receptor has 3 domains: the extracellular, transmembrane, and intracellular domains, all of which are necessary for receptor activation and intracellular signaling. In order to activate downstream signaling, receptors must dimerize utilizing the dimerization sub-domain (known as sub-domain II) located on the extracellular domain of the receptor.<sup>10</sup>
EGFR (HER1), HER3, and HER4 naturally exist in a “closed” conformation. In the closed position, the dimerization sub-domain (sub-domain II) is hidden or inaccessible, and as a result, the receptor is unable to form dimers. Ligand binding to these receptors leads to a conformational change, exposing sub-domain II and enabling the receptor to dimerize and initiate downstream signaling. HER2 is the only receptor in the HER family that exists in a continuously open conformation ready to dimerize without the need for ligand binding.<sup>3,11</sup>
HER2 dimerization: critical for tumor growth
When HER family members dimerize, the intracellular domains of the paired receptors are phosphorylated, resulting in the activation of cell proliferation and cell survival pathways.<sup>12</sup>
In HER2+ disease, the overexpression of HER2 is associated with overactive HER2 dimerization, abnormal signaling, and ultimately tumor growth.<sup>6</sup>
Dimerization: an important driver of oncogenic signaling
Please note: this video contains sound so please adjust volume
<video controls="" style="height: 269px;" id="ptzchapter2v2" poster="/research-education/hdis/images/ptzchapter2v2.jpg" class="video-js vjs-paused" preload="auto" height="269" width="490"> </video> http://www.biooncology.com/research-education/hdis/images/ptzchapter2v2.jpg
HER2 dimerization: a key component of oncogenic signaling in HER2+ breast cancer
The HER family
The HER family is composed of 4 receptor tyrosine kinases that must pair, or dimerize, to activate downstream signaling<sup>1</sup>:
EGFR (HER1)
HER2
HER3
HER4
The role of dimerization in HER2+ disease
Preclinical studies indicate that HER dimerization, or receptor pairing, is a critical step in HER activation.<sup>1</sup> While the receptors of the HER family are important mediators of normal cell growth and development, HER activation has also been implicated in cancer development and progression.<sup>10</sup>
In normal cell growth, dimerization is an essential requirement of HER functionality and signaling, and it occurs between 2 of the same receptors (homodimerization) or 2 different receptors (heterodimerization).<sup>1</sup>
However, in HER2+ disease, HER2 overexpression is associated with excessive dimerization that contributes to cell survival, cell proliferation, and tumorigenesis.<sup>6</sup>
http://www.biooncology.com/research-education/hdis/images/HERfamily.png <cite>The HER family of receptors.</cite>
(http://www.biooncology.com/research-education/hdis/images/HERfamily_lg.png) Ligand binding and HER activation
Each HER family receptor has 3 domains: the extracellular, transmembrane, and intracellular domains, all of which are necessary for receptor activation and intracellular signaling. In order to activate downstream signaling, receptors must dimerize utilizing the dimerization sub-domain (known as sub-domain II) located on the extracellular domain of the receptor.<sup>10</sup>
EGFR (HER1), HER3, and HER4 naturally exist in a “closed” conformation. In the closed position, the dimerization sub-domain (sub-domain II) is hidden or inaccessible, and as a result, the receptor is unable to form dimers. Ligand binding to these receptors leads to a conformational change, exposing sub-domain II and enabling the receptor to dimerize and initiate downstream signaling. HER2 is the only receptor in the HER family that exists in a continuously open conformation ready to dimerize without the need for ligand binding.<sup>3,11</sup>
HER2 dimerization: critical for tumor growth
When HER family members dimerize, the intracellular domains of the paired receptors are phosphorylated, resulting in the activation of cell proliferation and cell survival pathways.<sup>12</sup>
In HER2+ disease, the overexpression of HER2 is associated with overactive HER2 dimerization, abnormal signaling, and ultimately tumor growth.<sup>6</sup>
Dimerization: an important driver of oncogenic signaling
Please note: this video contains sound so please adjust volume
<video controls="" style="height: 269px;" id="ptzchapter2v2" poster="/research-education/hdis/images/ptzchapter2v2.jpg" class="video-js vjs-paused" preload="auto" height="269" width="490"> </video> http://www.biooncology.com/research-education/hdis/images/ptzchapter2v2.jpg